Nitric oxide availability in diabetes mellitus

Diabetes/Metabolism Reviews

Volumn 14, Issue 3, 1998, Pages 241-249

  Honing, Marina L H ^a,b   Morrison, Paul J ^b   Banga, Jan D ^a   Stroes, Erik S G ^a   Rabelink, Ton J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b U Gene Research   (Netherlands)

Author keywords

Diabetes; Endothelium; Insulin; Nitric oxide; Oxidative stress

Indexed keywords

ARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE;

AMINO ACID DEFICIENCY; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME DEFICIENCY; HYPERGLYCEMIA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS; HUMANS; INSULIN RESISTANCE; NITRIC OXIDE;

EID: 0031772518     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(1998090)14:3<241::AID-DMR216>3.0.CO;2-R     Document Type: Review

References (95)

1. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, and Deckert T: Features of endothelial dysfunction in early diabetic nephropathy. Lancet ii: 461-463, 1989.
2. Gimbrone MA: Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 75: 67b-70b, 1995.
3. Brusse R, and Fleming I: Regulation and functional consequences of endothelial nitric oxide formation. Ann Med 27: 331-340, 1995.
4. Loscalzo J: Nitric oxide and vascular disease. N Engl J Med 333: 251-253, 1995.
5. Adams MR, Jessup W, Hailstones D, and Celermajer DS: L-Arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules. Circulation 95: 662-668, 1997.
6. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, and Creager MA: Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97: 22-28, 1996.
7. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, and Creager MA: Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88: 2510-2516, 1993.
8. Calver A, Collier J, and Vallance P: Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 90: 2548-2554, 1992.
9. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, and Hayes JR: Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35: 771-776, 1992.
10. Watts GF, O'Brien SF, Silvester W, and Millar JA: Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidemia. Clin Sci 91: 567-573, 1996.
11. Williams SB, Cusco JA, Roddy MA, Johnstone MT, and Creager MA: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27: 567-574, 1996.
12. Smits P, Kapma JA, Jacobs MC, Lutterman J, and Thien T: Endothelium-dependent vascular relaxation in patients with type-I diabetes. Diabetes 42: 148-153, 1993.
13. Avogaro A, Francesco P, Valerio A, Miola M, Calveri M, Pavan P, Vicini P, Cobelli C, Tiengo A, Calò L, and Del Prato S: Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes 46: 1040-1046, 1997.
14. Elliott TG, Cockcroft JR, Groop PH, Viberti GC, and Ritter JM: Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci 85: 687-693, 1993.
15. Angulo J, Sánchez-Ferrer CF, Peiró C, Marin J, and Rodríguez-Manas L: Impairment of endothelium-dependent relaxation by increasing percentages of glycosylated human hemoglobin: possible mechanisms involved. Hypertension 28: 583-592, 1996.
16. Knowles RG, and Moncada S: Review article: nitric oxide synthases in mammals. Biochem J 298: 249-258, 1994.
17. Davies MG, Ramkumar V, Gettys TW, and Hagen PO: The expression and function of G-proteins in experimental intimai hyperplasia. J Clin Invest 94: 1680-1689, 1994.
18. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, and Cannon RO: Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 90: 35-41, 1994.
19. Mancusi G, Hutter C, Baumgartner-Parzer S, Schmidt K, Schutz W, and Sexl V: High-glucose incubation of human umbilical-vein endothelial cells does not alter expression and function either of G-protein alpha-subunits or of endothelial NO synthase. Biochem J 315: 281-287, 1996.
20. Pieper GM, Siebeneich W, Moore-Hilton G, and Roza AM: Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia 40: 910-915, 1997.
21. Pieper GM, and Peltier BA: Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 25: 397-403, 1995.
22. MacAllister RJ, Calver AL, Collier J, Edwards CM, Herreros B, Nussey SS, and Vallance P: Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effect? Clin Sci 89: 183-190, 1995.
23. Sobrevia L, Cesare P, Yudilevich DL, and Mann GE: Diabetes-induced activation of y+ and nitric oxide synthase in human endothelial cells: association with membrane hyperpolarization. J Physiol 489: 183-192, 1995.
24. 2 in high-glucose medium. Diabetes 44: 520-526, 1995.
25. Cosentino F, Hishikawa K, Katusic ZS, and Lüscher TF: High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96: 25-28, 1997.
26. Ceriello A, dello Russo P, Amstad P, and Cerutti P: High glucose induces antioxidant enzymes in human endothelial cells in culture: evidence linking hyperglycemia and oxidative stress. Diabetes 45: 471-477, 1996.
27. Donnini D, Zambito AM, Perrella G, Ambesi-Impiombato FS, and Curcio F: Glucose may induce cell death through a free radical-mediated mechanism. Biochem Biophys Res Commun 219: 412-417, 1996.
28. Giugliano D, Ceriello A, and Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267, 1996.
29. Ido Y, Kilo C, and Williamson JR: Cytosolic NADH/NAD+, free radicals, and vascular dysfunction in early diabetes mellitus. Diabetologia 40: S115-117, 1997.
30. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, and Tilton RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813, 1993.
31. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, and Baynes JW: Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43: 676-683, 1994.
32. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, and Bucala R: Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 89: 12043-12047, 1992.
33. Bucala R, Makita Z, Koschinsky T, Cerami A, and Vlassara H: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90: 6434-6438, 1993.
34. Brownlee M, Cerami A, and Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321, 1988.
35. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, and Galis ZS: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest 98: 2572-2579, 1996.
36. Schmidt AM, Hori O, Brett J, Van SD, Wautier JL, and Stern D: Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14: 1521-1528, 1994.
37. Bobbink IWG, de Boer HC, Tekelenburg WLH, Banga JD, and de Groot PG: Effect of extracellular matrix glycation on endothelial cell adhesion and spreading. Diabetes 46: 87-93, 1997.
38. Bobbink IWG, Tekelenburg WLH, Sixma JJ, de Boer HC, Banga JD, and de Groot PG: Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation. Biochem Biophys Res Commun 240: 595-601, 1997.
39. Schmidt K, Werner ER, Mayer B, Wachter H, and Kukovetz: Tetrahydrobiopterin-dependent formation of endothelium-derived relaxing factor (nitric oxide) in aortic endothelial cells. Biochem J 281: 297-300, 1992.
40. Consentino F, and Katusic Z: Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 91: 139-144, 1995.
41. Pieper GM: Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor tetrahydrobiopterin. J Cardiovasc Pharmacol 29: 8-15, 1997.
42. Derubertis FR, and Craven PA: Activation of protein kinase C in glomerular cells in diabetes: mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 43: 1-8, 1994.
43. Wolf BA, Williamson JR, Easom RA, Chang K, Sherman WR, and Turk J: Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin Invest 87: 31-38, 1990.
44. Kunisaki M, Bursell SE, Umeda F, Nawata H, and King GL: Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 43: 1372-1377, 1994.
45. Sharma K, and Ziyadeh FN: Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-β as a key mediator. Diabetes 44: 1139-1146, 1995.
46. Capdevila JH, Falck JR, and Estabrook RW: Cytochrome P450 and the arachidonate cascade. FASEB J 6: 731-736, 1992.
47. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, and Border WA: Expression of transforming growth factor-β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814-1818, 1993.
48. Beckman JS, and Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 271: C1424-C1437, 1996.
49. Pryor WA, and Squadrito GL: The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 268: L699-L722, 1995.
50. Moriel P, and Abdalla DS: Nitrotyrosine bound to beta-VLDL-apoproteins: a biomarker of peroxynitrite formation in experimental atherosclerosis. Biochem Biophys Res Commun 232: 332-335, 1997.
51. Leeuwenburgh C, Hardy MM, Hazen SL, Wagner P, Oh Ishi S, Steinbrecher UP, and Heinecke JW: Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 272: 1433-1436, 1997.
52. Evans P, Kaur H, Mitchinson MJ, and Halliwell B: Do human atherosclerotic lesions contain nitrotyrosine? Biochem Biophys Res Commun 226: 346-351, 1996.
53. Szabo C: The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia - reperfusion injury. Shock 6: 79-88, 1996.
54. Salman Tabcheh S, Guerin MC, and Torreilles J: Nitration of tyrosyl residues from extra- and intracellular proteins in human whole blood. Free Radic Biol Med 19: 695-698, 1995.
55. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, and Beckman JS: Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 298: 431-437, 1992.
56. Szabo C, Zingarelli B, O'Connor M, and Salzman AL: DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA 93: 1753-1758, 1996.
57. Pryor WA, and Squadrito GL: The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 268: L699-L722, 1995.
58. Thronalley PJ, McLellan AC, Lo TWC, Benn J, and Sönksen PH: Negative association between erythrocyte reduced glutathione concentration and diabetic complications. Clin Sci 91: 575-582, 1996.
59. Jan SK, and McVie R: Effect of glycemic control, race (white versus black), and duration of diabetes on reduced glutathione content in erythrocytes of diabetic patients. Metabolism 43: 306-309, 1994.
60. Frei B: Reactive oxygen species and antioxidant vitamins: mechanism of action. Am J Med 97(3A): 55-13S, 1994.
61. Donnini D, Zambito AM, Perrella G, Ambesi-Impiombato FS, and Curcio F: Glucose may induce cell death through a free radical-mediated mechanism. Biochem Biophys Res Commun 219: 412-417, 1996.
62. Pieper GM, Langenstroer P, and Siebeneich W: Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. Cardiovasc Res 34: 145-156, 1997.
63. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 45: 3-10, 1996.
64. Reaven GM, Chen I, Jeppesen J, Maheux P, and Krauss RM: Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 92: 141-146, 1993.
65. Kannel WB, and McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 241: 2035-2038, 1979.
66. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, and Bergman R: Insulin sensitivity and atherosclerosis. Circulation 93: 1809-1817, 1996.
67. Suzuki M, Shinozaki K, Kanazawa A, Hara Y, Hattori Y, Tsushima M, and Harano Y: Insulin resistance as an independent risk factor for carotid wall thickening. Hypertension 28: 593-598, 1996.
68. DeFronzo RA, and Ferranini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194, 1991.
69. Yudkin JS: Is insulin vasculotoxic? Diabetologia 40: S145-S146, 1997.
70. Anderson EA, and Mark AL: The vasodilator action of insulin: implications for the insulin hypothesis of hypertension. Hypertension 21: 136-141, 1993.
71. Dunbar JC, O'Leary DS, Wang G, and Wright-Richey J: Mechanisms mediating insulin-induced hypotension in rats: a role for nitric oxide and autonomic mediators. Acta Diabetol 33: 263-268, 1996.
72. - excretion. Metabolism 46: 406-409, 1997.
73. Scherrer U, Randin D, Vollenweider P, Vollenweider L, and Nicod P: Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 94: 2511-2515, 1994.
74. Steinberg HO, Brechtel G, Johnson A, Fineberg N, and Baron AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 94: 1172-1179, 1994.
75. Trovati M, Massucco P, Mattiello L, Piretto V, Cavalot F, Mularoni E, and Anfossi G: The insulin-induced increase of guanosine-3′,5′-cyclic monophosphate in human platelets is mediated by nitric oxide. Diabetes 45: 768-770, 1996.
76. Balon TW, and Nadler JL: Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol 82: 359-363, 1997.
77. Young ME, Radda GK, and Leighton B: Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem J 322: 223-228, 1997.
78. Petrie JR, Ueda S, Webb DJ, Elliott HL, and Connell JMC: Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 93: 1331-1333, 1996.
79. Natali A, Taddei S, Galvan AQ, Camastra S, Baldi S, Frascerra S, Virdis A, Sudano I, Salvetti A, and Ferrannini E: Insulin sensitivity, vascular reactivity, and clamp-induced vasodilation in essential hypertension. Circulation 96: 849-855, 1997.
80. Stehouwer CDA, and Schaper NC: The pathogenesis of vascular complications of diabetes mellitus: one voice or many? Eur J Clin Invest 26: 535-543, 1996.
81. Utriainen T, Makimattila S, Virkamaki A, Bergholm R, and Yki-Jarvinen H: Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. Diabetologia 39: 1477-1482, 1996.
82. 3H]-deoxyglucose muscle uptake. Am J Hypertens 10: 683-686, 1997.
83. Nagasaka S, Iwamoto Y, Ishikawa S, Kuzuya T, and Saito T: Efficacy of troglitazone measured by insulin resistance index. Lancet 350: 184, 1997.
84. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, and Ganz P: The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332: 488-493, 1995.
85. Leung WH, Lau CP, and Wong CK: Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 341: 1496-1500, 1993.
86. Stroes ESG, Koomans HA, de Bruin TWA, and Rabelink TJ: Vascular function in the forearm of hypercholesterolemic patients of and on lipid-lowering medication. Lancet 346: 467-471, 1995.
87. Mancini GBJ, Henry GC, Macya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, and Pitt B: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 94: 258-265, 1996.
88. Martin A, Foxall T, Blumberg JB, and Meydani M: Vitamin E inhibits low-density-lipoprotein-induced adhesion of monocytes to human aortic endothelial cells in vitro. Arterioscler Thromb Vasc Biol 17: 429-436, 1997.
89. Inoue S, and Kawanishi S: Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide. FEBS lett 371: 86-88, 1995.
90. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, and Rabelink T: Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 99: 41-46, 1997.
91. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, and King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ-inhibitor. Science 272: 728-731, 1996.
92. Ohgushi M, Hugiyama K, Fukunaga K, Murohara T, Sugiyama S, Miyamoto E, and Yasue H: Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modified LDL. Arterioscler Thromb Vasc Biol 13: 1525-1532, 1993.
93. Hasan K, Heesen BJ, Corbett JA, McDaniel ML, Chang K, Allison W, Wolffenbuttel BHR, Williamson JR, and Tilton RG: Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol 249: 101-106, 1993.
94. Betteridge DJ: Lipids and atherogenesis in diabetes mellitus. Atherosclerosis 124: S43-S47, 1996.
95. Taskinen MR: Triglyceride is the major atherogenic lipid in NIDDM. Diabetes/Metab Rev 13: 93-98, 1997.